JNJ

227.49

+0.41%↑

ABT

92.08

-1.59%↓

MDT

83.96

+0.3%↑

113.39

-7.28%↓

VEEV

155.8

-6.99%↓

JNJ

227.49

+0.41%↑

ABT

92.08

-1.59%↓

MDT

83.96

+0.3%↑

113.39

-7.28%↓

VEEV

155.8

-6.99%↓

JNJ

227.49

+0.41%↑

ABT

92.08

-1.59%↓

MDT

83.96

+0.3%↑

113.39

-7.28%↓

VEEV

155.8

-6.99%↓

JNJ

227.49

+0.41%↑

ABT

92.08

-1.59%↓

MDT

83.96

+0.3%↑

113.39

-7.28%↓

VEEV

155.8

-6.99%↓

JNJ

227.49

+0.41%↑

ABT

92.08

-1.59%↓

MDT

83.96

+0.3%↑

113.39

-7.28%↓

VEEV

155.8

-6.99%↓

Начало・Списък с акции・Lisata Therapeutics

L
Lisata Therapeutics

Отворен

3.32 3.75

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.2

Максимум

3.32

Ключови измерители
By Trading Economics
Приходи	1.3M -3M
Продажби	100K 100K
Марж на печалбата	-2,954
Служители	21

Дивиденти
By Dow Jones
Следващи печалби	7.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-15M 24M
Предишно отваряне	-0.43
Предишно затваряне	3.32

Lisata Therapeutics Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

23.04.2026 г., 00:00 ч. UTC

Значими събития в новините

Australian Flash PMI Bounce in April Conceals Deeper Worries

22.04.2026 г., 23:33 ч. UTC

Печалби

SK Hynix Posts Record Quarterly Results Amid AI Boom

22.04.2026 г., 22:40 ч. UTC

Печалби

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

22.04.2026 г., 22:10 ч. UTC

Придобивния, сливания и поглъщания

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

22.04.2026 г., 21:11 ч. UTC

Печалби

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

22.04.2026 г., 21:01 ч. UTC

Печалби

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

22.04.2026 г., 23:46 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

22.04.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

22.04.2026 г., 23:34 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

22.04.2026 г., 23:16 ч. UTC

Печалби

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

22.04.2026 г., 23:15 ч. UTC

Печалби

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

22.04.2026 г., 22:54 ч. UTC

Печалби

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

22.04.2026 г., 22:54 ч. UTC

Печалби

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

22.04.2026 г., 22:52 ч. UTC

Печалби

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

22.04.2026 г., 22:51 ч. UTC

Печалби

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

22.04.2026 г., 22:31 ч. UTC

Печалби

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

22.04.2026 г., 22:31 ч. UTC

Печалби

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

22.04.2026 г., 22:30 ч. UTC

Печалби

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

22.04.2026 г., 22:30 ч. UTC

Печалби

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

22.04.2026 г., 22:29 ч. UTC

Печалби

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

22.04.2026 г., 22:28 ч. UTC

Печалби

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

22.04.2026 г., 22:28 ч. UTC

Печалби

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

22.04.2026 г., 22:27 ч. UTC

Печалби

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

22.04.2026 г., 22:06 ч. UTC

Пазарно говорене

Печалби

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

22.04.2026 г., 21:55 ч. UTC

Придобивния, сливания и поглъщания

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

22.04.2026 г., 21:47 ч. UTC

Печалби

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22.04.2026 г., 21:37 ч. UTC

Печалби

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

22.04.2026 г., 21:34 ч. UTC

Печалби

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

22.04.2026 г., 21:29 ч. UTC

Печалби

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22.04.2026 г., 21:20 ч. UTC

Пазарно говорене

Печалби

Tesla Expands Manufacturing to Chips -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Lisata Therapeutics Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на Lisata Therapeutics през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Печалба преди облагане с данъци

Продажби

Оперативна печалба

Относно Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.